Evidence map›Paper›PMID 39472402›Full record

ArticleInternational urology and nephrology2025

Does the hemodialysis program affect the testosterone serum level in patients with end-stage renal disease?

Mahmoud Mustafa, Imad Khaznah, Donya Hrezat, Lama Abu Obaida, Amir Aghbar

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mahmoud MustafaDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. dr_mahmoud681@yahoo.com.ORCID http://orcid.org/0000-0001-9292-6262
Imad KhaznahDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Donya HrezatDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Lama Abu ObaidaDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Amir AghbarDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.ORCID http://orcid.org/0000-0002-4402-7278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the effect of high flux membrane hemodialysis on total serum testosterone (TST) levels in male patients with end-stage renal disease (ESRD).

methodsThe study included 60 male ESRD patients with a mean age of 54.02 ± 13.40 years, undergoing a standard hemodialysis program et al. Najah National University Hospital. All patients underwent three weekly sessions of four hours each using high flux membrane hemodialysis. TST and hematocrit (Hct) levels were measured before and after hemodialysis. Patients with prostate cancer, liver insufficiency, prior prostate surgery, or those on androgen therapy were excluded. The study assessed changes in TST and Hct levels and their correlation.

resultsPost-dialysis, there was a significant increase in serum testosterone levels from 3.13 ± 1.44 ng/ml to 4.17 ± 2.04 ng/ml (r = 0.78, p = 0.001). Hematocrit levels also rose significantly from 32.31% ± 3.90% to 35.27% ± 4.89% (r = 0.754, p = 0.001). The percentage change in TST and Hct levels was 35 ± 0.33% and 9 ± 0.1%, respectively, with a correlation between these changes (r = 0.277, p = 0.032).

conclusionHigh flux membrane dialysis did not filter testosterone molecules, and the significant increase in TST levels post-dialysis is likely due to hemoconcentration. Since many patients had low or borderline TST levels before dialysis, androgen supplementation may offer clinical benefits.

Indexed as

Kidney Failure, ChronicRenal DialysisTestosteroneAdultAgedHematocritHumansMaleMiddle AgedTestosteroneAndrogen supplementationEnd-stage renal disease (ESRD)HemoconcentrationHigh flux membrane dialysisSerum testosterone

Identifiers

PMID39472402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.